Funder: METAvivor
Due Dates: March 12, 2025 (Letter of Intent) | August 20, 2025 (Internal Submission) | December 30, 2025 (Funding Organization's Deadline)
Funding Amounts: Up to $200,000 total over two years; includes direct costs and up to 5% indirect costs.
Summary: Supports early-career investigators conducting innovative research to advance understanding and treatment of metastatic breast cancer.
Key Information: Only projects focused on established metastatic (stage IV) breast cancer are eligible; prevention or standard diagnosis projects are not considered.